It may be possible to train music generation models which have a shot at treating, and perhaps even preventing Alzheimer's.
It'd take ~$5m to build and run trials for what could become one of the most widely deployed public health interventions.
jajoo.sh/gamma
Samarth Jajoo retweeted
I wonder if an Indian deeptech fund run by actual deeptech founders could raise $100m... @akadogluk @Itamar_Bitan and I have been talking about this. Maybe @ashleevance can find us some LPs.
We should call it the Cowardice Fund!
infinitesunrise.com/p/overco…
Why are Indian VCs so afraid to take risk and make money?
Someone should go to India and take risk and make money.
Our story - corememory.com/p/a-new-india…
The team:
- computationally designed and tested ~1300 vaccine constructs in animals
- screened ~5000 novel LNP formulations in the wet lab
- built a mRNA-LNP manufacturing facility which can produce a million doses every year
and now, we are well into our first human trial!
On August 31, the first two participants were injected with @PopVaxIndia’s first fridge-stable RNA vaccine candidate in a Phase I clinical trial in Australia. We built this vaccine at our RNA Foundry in Hyderabad – from computational design to GMP manufacturing. Here's how:
Samarth Jajoo retweeted
I am hiring a talented and tasteful full-stack filmmaker for a three-month fellowship @PopVaxIndia, full-time in Hyderabad, to help the world imagine what the future of medicine will look like in our new world of abundant intelligence. We think medicine will be increasingly personalized and preventative, and the mechanics of healthcare will have to be entirely transformed to make that possible. A lot of this will look more like making science fiction than producing launch videos, though there will be some of that as well.
I'm looking for someone who is as comfortable shooting and editing a short film entirely in real life as they are generating it entirely with AI, with the ability to seamlessly embed the one medium in the other. If this is you, email me at film [at] popvax dot com with a few samples, ideally both writing and video. This is a paid position, and it has the potential (but not the requirement) to convert to a long-term role if there is mutual alignment.
My brother @SahajSankaran and I write and direct a little on the side -- see youtube.com/@honestyontape -- so, for better or worse, I will be quite opinionated about what we put out. If this goes well, it will be a deep and fulfilling collaboration on all aspects of the creative process, from the writing to the final cut.
I should have done this a long time ago (many such cases). This will be a lot of fun!
@pbshgthm @ashleevance @oshosidhant
@anupamsidhant @pavlikam @ABiggerSpalash @neervj @neilshroff @sidin
Samarth Jajoo retweeted
There’s lots of buzz around agentic harnesses for robots, particularly for long horizon tasks that require complex reasoning and memory. But what will it really take to turn a reasoning agent into a reactive, reliable and low-latency robot policy?
In our new paper, workspace models, we design a new memory architecture that acts as a latent harness for stronger reasoning models. Here’s why we think this might be the way forward:
(1/9)
Samarth Jajoo retweeted
AI allows us to design & develop life-saving medicines in months, yet India takes a year to approve clinical trials – Australia & China take weeks. Honoured to co-write an op-ed in @EconomicTimes with @KiranShaw on decentralising our trial framework to accelerate Indian biotech.
While Yun is in the news for yet again coming up with clever ways to do variant effect prediction, I want to remind folks about a really neat result from his lab ~4 years ago:
biorxiv.org/content/10.1101/…
Protein language models learn multiple conformations!
We are thrilled to share that our GPN-Star manuscript is now published and freely available:
doi.org/10.1038/s41586-026-1…
(1/n)
How do we disentangle them? I think a method that figures out a way to do that is our best shot at fast progress in generating multiple conformations / modelling conformational diversity in proteins.
@yun_s_song curious if you've thought about this more!
Amazing!
I think the technology Anand and Melody create will help illuminate the mechanism behind pathologies and ultimately lead to diagnostics + therapeutics we otherwise wouldn't even be able to imagine.
Hello world! We’re @MelodyFRO.
Most wearables don’t go far beyond heart rate and activity.
Lab diagnostics paint a deeper picture but don’t read continuously.
Melody is building biosensors, devices, and standards to bridge this gap.
Hear our story at melodyfro.org
Samarth Jajoo retweeted
Excited to share our work on a model for mapping molecules to olfactory receptors to perception, out today! Check out the link in thread ⬇️
Out today in Cell Systems: the final version of our work on biologically-inspired models for predicting how molecules smell!
With @SeyoneC and @jdthamores
Incredible work, and another win for inference time optimization!
Samarth Jajoo retweeted
My wonderful brother @SahajSankaran and I are pleased to release The Project, a new comedy pilot we wrote and directed about a group of villagers who start a fake consulting firm in a last-ditch attempt to save their village from demolition. Take a look!
(THIS IS SATIRE) Progress has costs. Sometimes, those costs are jobs. Sometimes, they are people. Sometimes, it can be whole villages also. What to do? As the village of Chanala learns, the bulldozer of development cannot be stopped, certainly not by lying in front of it. (1/3)
Satyagraha 2026 (Honesty is Best presents The Project)
Based. Who is signing up to run a phage display / yeast display campaign to verify on-target activity for these?
The Human Bindome: A Proteome-scale Atlas of Designed Binder Candidates
1. The paper introduces the Human Bindome: 306,146 designed, genetically encodable protein binder candidates (fixed length 90 aa) spanning 8,296 human proteins, each with an explicit sequence, a predicted binder–target complex structure, and in silico confidence metrics.
2. Core motivation: conventional antibody reagents are often expensive, variably characterized, and frequently lack disclosed sequences, contributing to reproducibility issues; the Bindome aims to provide openly specified alternatives at proteome scale.
3. Methodologically, they scale the experimentally benchmarked BindCraft pipeline (reported prior success rates 10–100% depending on target) by adding automated domain-level target selection and an accelerated parallel implementation suitable for proteome-scale execution.
4. Target selection is driven by AlphaFold DB full-length models plus PAE matrices: proteins are segmented into domains via PAE-based clustering, and “targetable domains” are filtered for confident folding, compactness, contact density, acceptable length, and exclusion of membrane-embedded regions.
5. A key engineering detail: designing against cropped domains makes computation cheaper and enables multiple distinct sites per protein, but can create clashes with other parts of the full-length protein; they address this by superimposing each complex onto the full-length model and rejecting sterically clashing designs unless the clash is in low-confidence regions (high PAE / low pLDDT).
6. All candidates pass unchanged BindCraft stringency thresholds, including binder monomer fold confidence (pLDDT > 0.8) and interaction placement confidence (normalized iPAE < 0.35); distributions are not piled up at cutoffs (medians pLDDT 0.92, iPAE 0.23), enabling within-target prioritization.
7. Coverage numbers: the “targetable proteome” is 10,664 of 20,279 proteins; Bindome covers 77.8% of that targetable set and 40.9% of the full human proteome, with ~37 candidates per target protein on average.
8. Structural breadth: mapping domains to CATH superfamilies suggests 78.2% of superfamilies represented in the human target-domain set have at least one binder candidate; uncovered regions are largely outside the current scope (notably integral membrane proteins).
9. Epitope biology: binder epitopes show convergence within domain families (e.g., grooves/pockets in WD40 and bromodomains; broad kinase-domain surfaces), and epitope residues are significantly more evolutionarily conserved than matched surface controls—more consensus across binders corresponds to higher conservation.
10. Functional relevance and perturbation potential: epitopes often overlap annotated functional sites (PTMs, protein–protein interfaces, ligand-binding sites, DNA-binding regions), and 26% of ASD-annotated allosteric targets have at least one binder overlapping an allosteric site; examples include candidates positioned to occlude TP53 DNA-binding or disrupt SOD1 interaction interfaces.
11. Interface properties vs native PPIs: binder interfaces are native-like in mean area and slightly more polar, but show a strong bias toward helix-mediated contacts on the designed binder side; binder folds are often not globally novel, yet interfaces appear largely novel by interface similarity comparisons.
12. Accessibility is treated as a first-class output: a free web interface supports ranking/inspection and bulk downloads; a standardized 3D-Beacons API enables programmatic retrieval; and an MCP server allows natural-language “agentic” querying via LLM tools.
13. ML utility: the dataset is released with leakage-controlled train/val/test splits based on interface clustering (205,553 train; 21,205 val; 21,955 test), designed to support development/evaluation of next-generation binder design models.
💻Code: github.com/wejulius/Bindome
📜Paper: biorxiv.org/content/10.64898…
#ProteinDesign #ComputationalBiology #StructuralBioinformatics #AlphaFold #ProteinBinders #Reproducibility #FunctionalGenomics #DrugDiscovery #MachineLearning
Most of protein design works this way now! We just prompt tune structure prediction models.
For example: blog.escalante.bio/minibinde…
A little bit about what I have been working on :)
I never met my grandfather.
He died of pancreatic cancer when my father was just 19. Today, Yash Bindal, 33, father to 18-month-old Maya, faces the same fate.
@PopVaxIndia is using AI to make him a personalized generative medicine to extend his life.
chronicles.popvax.com/p/one-…
Samarth Jajoo retweeted
Excited to share this work with @yoakiyama @ChoYehlin @jajoosam @sokrypton
We find that protein language models trained solely on individual protein sequences, implicitly learn the interface contacts of homo-oligomeric assemblies! As the model scales up, more interface signals pop up.
However, we also notice some proteins PDB database marked as homo-oligomers are missing these interface signals. This took us on the journey to investigate the emergence and absence of homo-oligomeric contacts in pLMs.
biorxiv.org/content/10.1101/…
If you live long enough, cancer will come for you too. But if you know soon enough, you can almost certainly do something about it.
We must test early and often. Hiya writes a deeply personal account:
Replying to @jainhiya_
In the essay I never thought I would write, I talk about my experience peaking at the "bad side" of medicine and present a defense for blood based early detection (3/3)
Link: mundane.beauty/p/the-bad-sid…
Samarth Jajoo retweeted
This morning, one of my closest friends called me sounding concerned. His doctor had informed him that he had a fatty liver. A decade ago that might have been scary news; but today I was able to reassure him that it's something we can easily reverse with medication.
Hearing the tension melt from his voice made me genuinely happy. And it only reinforces my belief that the fruits of the pharma industry really are a gift from God, especially when they touch the lives of people we care about.





















